---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026878"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:54:31.465081+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Journey Medical launches Emrosi for rosacea; first prescriptions filled

## Summary
- Emrosi (40 mg minocycline HCl modified-release) launched for inflammatory lesions of rosacea in adults.
- First prescriptions filled; initial distribution to specialty pharmacy chains ongoing.
- FDA approval was obtained in November 2024; Emrosi is the lowest-dose oral minocycline for rosacea.
- Clinical trials showed significantly superior outcomes vs. Oracea and placebo with comparable safety.

## SEC filing metadata
- accession: 0001104659-25-026878
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465925026878/0001104659-25-026878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465925026878/tm2510103d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026878
- JSON: https://secwatch.observer/filing/0001104659-25-026878.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.